US6893636B2
(en)
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP1746107B1
(de)
|
1998-04-02 |
2014-12-17 |
Genentech, Inc. |
Antikörpervarianten und deren Fragmente
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
NZ539776A
(en)
*
|
1999-01-15 |
2006-12-22 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US6193892B1
(en)
|
1999-03-03 |
2001-02-27 |
Promega Corporation |
Magnetic separation assembly and method
|
US7416726B2
(en)
*
|
2000-04-13 |
2008-08-26 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
FR2836146B1
(fr)
*
|
2002-02-15 |
2005-01-07 |
Urrma R & D |
IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
EP1578447A4
(de)
*
|
2002-10-31 |
2009-06-03 |
Genentech Inc |
Verfahren und zusammensetzungen zur erhöhung der antikörper-produktion
|
AU2004204494B2
(en)
*
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
CA2529945A1
(en)
*
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
CA2534959A1
(en)
*
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
BRPI0418286A
(pt)
*
|
2003-12-30 |
2007-05-02 |
Merck Patent Gmbh |
proteìnas de fusão de il-7
|
US20050255533A1
(en)
*
|
2004-02-10 |
2005-11-17 |
Brendan Bioscience, Llc |
Comprehensive food allergy test
|
US8309318B2
(en)
*
|
2004-02-10 |
2012-11-13 |
Brendan Bioscience, Llc |
Detection of antigen specific immunocomplexes
|
US7521542B2
(en)
|
2004-05-10 |
2009-04-21 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
ES2426817T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
US20060067930A1
(en)
*
|
2004-08-19 |
2006-03-30 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
AU2005282700A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
EP1674479A1
(de)
*
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
*
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
AU2006239851B2
(en)
*
|
2005-04-26 |
2011-06-16 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
DK2573114T3
(en)
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
CA2644903A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
GB2436616A
(en)
|
2006-03-29 |
2007-10-03 |
Inverness Medical Switzerland |
Assay device and method
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
EP4342995A2
(de)
|
2006-03-31 |
2024-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
|
EP2021029B1
(de)
*
|
2006-05-26 |
2014-06-11 |
MacroGenics, Inc. |
Humanisierte fc-gamma-riib-spezifische antikörper und verfahren zu ihrer anwendung
|
EP2032159B1
(de)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
WO2008007159A1
(en)
*
|
2006-07-14 |
2008-01-17 |
Eötvös Lorand University |
Measurement of complement activation products on antigen arrays
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
EP3127921A1
(de)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
|
MX2010003450A
(es)
|
2007-09-26 |
2010-04-27 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo modificada.
|
US8795667B2
(en)
*
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
US8802093B2
(en)
|
2008-04-02 |
2014-08-12 |
Macrogenics, Inc. |
HER2/neu-specific antibodies and methods of using same
|
EP3045475B1
(de)
|
2008-04-02 |
2017-10-04 |
MacroGenics, Inc. |
Bcr-komplex-spezifische antikorper und verfahren zu ihrer verwendung
|
CA2726845C
(en)
*
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
TWI646193B
(zh)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
抗體恆定區域改變體
|
US10150808B2
(en)
*
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
PE20130479A1
(es)
|
2010-03-04 |
2013-05-12 |
Macrogenics Inc |
Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
CN103154025B
(zh)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
MX336740B
(es)
|
2011-03-29 |
2016-01-29 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
MX347818B
(es)
|
2011-05-21 |
2017-05-15 |
Macrogenics Inc |
Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
|
HRP20211641T1
(hr)
|
2012-07-13 |
2022-02-04 |
Roche Glycart Ag |
Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
US9908938B2
(en)
|
2013-03-14 |
2018-03-06 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
SG11201702544WA
(en)
|
2014-09-29 |
2017-04-27 |
Univ Duke |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
IL262396B2
(en)
|
2016-04-15 |
2023-09-01 |
Macrogenics Inc |
New b7-h3 binding molecules, drug-antibody conjugates and their uses
|